Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

Phase 3

Active, not recruiting

Conditions: Metastatic Colorectal Cancer
Metastatic Colon Cancer

Interventions: Drug: Placebo
Drug: Fruquintinib

First Posted Date: 2020-03-26

Last Posted Date: 2023-09-14

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 691

Registration Number: NCT04322539

Locations: 🇺🇸
Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East), West Palm Beach, Florida, United States
🇺🇸
Sarah Cannon Research Institute-S-Ft. Myers (FCS South), Fort Myers, Florida, United States
🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States

and more 150 locations

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colo-rectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2020-03-05

Last Posted Date: 2021-11-03

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 110

Registration Number: NCT04296019

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Phase 2

Conditions: Metastasis Colorectal Cancer

Interventions: Drug: fruquintinib
Drug: Sintilimab

First Posted Date: 2019-11-26

Last Posted Date: 2019-11-26

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT04179084

Locations: 🇨🇳
China PLAGH, Beijing, China

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3

Conditions: Advanced Malignancies

Interventions: Drug: Tislelizumab
Drug: Pamiparib
Drug: Sitravatinib
Drug: BGB-15025
Drug: Zanidatamab
Drug: Temozolomide
Drug: Ociperlimab
Drug: BAT1706
Drug: Fruquintinib
Drug: BGB-A445
Drug: Surzebiclimab
Drug: Lenvatinib
Drug: LBL-007

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-16

Lead Sponsor: BeiGene

Target Recruit Count: 300

Registration Number: NCT04164199

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

and more 70 locations

Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma

Phase 2

Conditions: Biliary Tract Adenocarcinoma

Interventions: Drug: Fruquintinib

First Posted Date: 2019-11-08

Last Posted Date: 2019-11-08

Lead Sponsor: Sichuan University

Target Recruit Count: 33

Registration Number: NCT04156958

Locations: 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Jilin Cancer Hospital, Chang chun, Jilin, China
🇨🇳
Hebei Tumor Hospital, Shijiazhuang, Hebei, China

and more 4 locations

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Geptanolimab Injection
Drug: Fruquintinib

First Posted Date: 2019-06-06

Last Posted Date: 2021-02-10

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT03977090

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Phase 1

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: GB226
Drug: Fruquintinib

First Posted Date: 2019-06-06

Last Posted Date: 2021-03-03

Lead Sponsor: Genor Biopharma Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT03976856

Locations: 🇨🇳
Shanghai chest hospital, Shanghai, Shanghai, China

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Phase 2

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2018-09-26

Last Posted Date: 2019-11-19

Lead Sponsor: Hutchison Medipharma Limited

Registration Number: NCT03684967

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Fruquintinib
Drug: Gefitinib

First Posted Date: 2016-11-29

Last Posted Date: 2019-11-15

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 50

Registration Number: NCT02976116

Locations: 🇨🇳
The First Hospital of Zhejiang University, Hangzhou, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: NSCLC

Interventions: Drug: Placebo
Drug: Fruquintinib

First Posted Date: 2016-02-25

Last Posted Date: 2019-02-12

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 527

Registration Number: NCT02691299

Locations: 🇨🇳
The First Affiliated Hosptial of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
307 Hospital of PLA, Beijing, Beijing, China

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy